AstraZeneca PLC and immunotherapy specialist Transgene SA are to work together to develop armed oncolytic vaccinia virus candidates.
The companies announced on 2 May that they have signed a deal to collaborate on research, plus an option and exclusive license agreement to co-develop five candidates, which